Attributable cost of methicillin resistance: an issue that is difficult to evaluate

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Health Economics

Background:

• Methicillin resistance poses a significant challenge in healthcare settings.
• Ventilator-associated pneumonia (VAP) is a common hospital-acquired infection.
• Accurate estimation of VAP consequences and costs is crucial for effective resource allocation.

Purpose of the Study:

• To highlight the difficulties in estimating the consequences and costs associated with methicillin resistance.
• To identify and discuss key confounding factors that bias estimates in methicillin-resistant VAP (MR VAP) studies.
• To guide researchers and clinicians in conducting more accurate assessments.

Main Methods:

• Literature review focusing on studies comparing methicillin-resistant VAP (MR VAP) and methicillin-sensitive VAP (MS VAP).
• Analysis of patient characteristics and outcomes in existing VAP research.
• Identification of common biases and confounding variables in cost-effectiveness analyses.

Main Results:

• Significant differences exist between patients with MR VAP and MS VAP.
• These differences frequently lead to biased estimates of treatment costs and patient outcomes.
• Several key confounding factors, if not properly addressed, can skew research findings.

Conclusions:

• Estimating the true burden of MR VAP is challenging due to inherent patient and pathogen differences.
• Awareness and control of confounding factors are essential for accurate economic and clinical impact assessments.
• Further research methodologies should prioritize robust adjustment for confounding variables to improve VAP cost and consequence estimations.